FEBS Letters 587 (2013) 98–103

FEBS Letters

journal homepage: www.FEBSLetters.org

Role of Rev-erbα domains for transactivation of the connexin43 promoter with Sp1

Hiromitsu Negoro [a,b], Takeshi Okinami [a], Akihiro Kanematsu [a,c], Masaaki Imamura [a], Yasuhiko Tabata [b], Osamu Ogawa [a,*]

[a] Department of Urology, Kyoto University, Graduate School of Medicine, Sakyo, Kyoto 606-8507, Japan
[b] Department of Biomaterials, Institute for Frontier Medical Sciences, Kyoto University, Sakyo, Kyoto 606-8507, Japan
[c] Department of Urology, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan

ARTICLE INFO

Article history:
Received 23 August 2012
Revised 15 October 2012
Accepted 9 November 2012
Available online 28 November 2012

Edited by Ivan Sadowski

Keywords:
Connexin43
Nuclear receptor
Rev-erbα
Rev-erbβ
Sp1

ABSTRACT

Rev-erbα, a component of the circadian clock, has also been known as a nuclear receptor that lacks activation function domain 2, functioning as a ligand-dependent transcriptional repressor. However, we recently reported that Rev-erbα activates *connexin43* transcription by forming a complex with Sp1. Here we show that heme, a REV-ERB ligand, is dispensable for this novel mechanism and that Rev-erbβ, having homologies with Rev-erbα, does not activate *connexin43*, but competes with the Rev-erbα/Sp1. The A/B region of Rev-erbα, which is not conserved in Rev-erbβ, is a crucial activating domain, while the ligand binding domain, conserved in Rev-erbβ, functions as a competitor.

1. Introduction

Rev-erbα and Rev-erbβ, initially identified as orphan nuclear receptors Nr1d1 and Nr1d2, are also components of the circadian clock, have important roles in metabolism and cellular differentiation [1–4]. The circadian clock is genetic machinery that generates autonomous genetic oscillations in systemic organs by coordination of transcriptional activators (Bmal1 and Clock) and repressors (Per1–3 and Cry1, 2) that regulate other genes by binding to E boxesin promoter regions [5,6]. Concurrently, Rev-erbα/β and Rorα/β/γ have been shown to tune the amplitude and the phase of the circadian clock, or control transcription of other non-clock genes, by binding to RORE sites of target genes [1,3,7,8].

Nuclear receptors modulate transcriptional activity by binding to specific ligands such as steroid hormones, thyroid hormone, vitamin D and retinoids, and function either as activators or repressors by recruiting co-activators or co-repressors, respectively [9,10]. Rev-erbα and Rev-erbβ have been considered to be ligand-dependent transcriptional repressors since they lack a canonical activation function domain 2 (AF-2) [11,12] and their repressive effects by recruiting nuclear receptor co-repressor/histone deacetylase 3 depend on their ligand of heme [13–16].

However, in a sharp contrast to these previous notions, we have revealed that Rev-erbα functions as an activator for *connexin43* gene (*Cx43*) by forming a complex with Sp1 in HEK293T cells and bladder smooth muscle cells [17]. Importantly, this effect required proximal Sp1 sites, but no RORE sequences, on the *Cx43* promoter.

Sp1 is an Sp/KLF family transcriptional factor that regulates expression of multiple genes with GC-rich sequences, that is, Sp1 binding sites, on their promoter regions [18,19]. The Sp1-dependent transactivation of GC-rich promoter sequences is reported with various nuclear proteins as well as basal transcription factors [11]. Interaction between Sp1 and nuclear receptors are reported with RAR, RXR, ERs and PPAR, which possess common structures of nuclear receptor domains including an A/B region (AB), a DNA binding domain (DBD), a hinge region (H) and a ligand binding domain (LBD) [20–22].

Here, we investigate the detailed mechanism by which Rev-erbα and Sp1 complex to transactivate the *Cx43* promoter in

Abbreviations: Cx43, connexin43; AB, A/B region; DBD, DNA binding domain; H, hinge region; LBD, ligand binding domain; ER, Estrogen Receptor

* Corresponding author. Address: Department of Urology, Kyoto University, Graduate School of Medicine, 54 Shogoin-Kawara-cho, Sakyo-ku, Kyoto, Japan. Fax: +81 75 761 3441.
E-mail address: ogawao@kuhp.kyoto-u.ac.jp (O. Ogawa).

0014-5793/$36.00
http://dx.doi.org/10.1016/j.febslet.2012.11.021

comparison with Rev-erbβ, and clarify the roles of Rev-erbα domains for the process.

2. Methods

Plasmid constructs: The mouse pGL-2-Cx43 promoter–reporter (pCx43-1686/+165-luc), constructed by Dr. S.J. Lye [23], was a kind gift from Dr. J. Yao (University of Yamanashi, Yamanashi, Japan). The pRL-TK (Promega, Madison, WI) were used as a transfection efficacy control. The Sp1 expression vector, constructed by Dr. Suske [24] was a kind gift from Dr. Toguchida (Frontier Medical Sciences, Kyoto University, Kyoto, Japan). The expression vector of Rev-erbα and Rev-erbβ was purchased from Open Biosystems (Huntsville, AL). Site-directed mutagenesis, deletion and addition of aimed sequences were performed using a mutagenesis basal kit (Takara) according to the manufacturer's protocol. These mutants were all verified by sequencing.

Promoter–reporter assay: Reporter plasmids with various expression vectors were transfected into HEK293T cells in 24-well plates using Fugene6 (Roche) in DMEM with 10% fetal calf serum (FCS) according to the manufacturer's protocol. pCx43-luc or pGL2-basic 100 ng and pTK-RL 5 ng were transfected with various amounts of expression vectors (total 250 ng). Plasmid dosage was kept constant by EGFP-N1 vector. Lysates were harvested 48 h post-transfection, and the luciferase activity was measured using a dual luciferase assay reagent (Promega). For the hemin treatment, medium was changed to various concentration of hemin in DMEM with 10% FCS at 24 h after the transfection and kept for 24 h. For SR8278 (Sigma) and GSK4112 (Sigma) treatment, 24 h after the transfection medium was changed to DMEM with 10% FCS containing 10 μM of each reagent and incubated for additional 24 h.

Immunoblotting: Preparation of whole-cell lysates from HEK293T cells, and the immunoblotting procedure were performed as previously described [17,25]. Briefly, cells were lysed in radio-immunoprecipitation assay (RIPA) buffer containing protease inhibitors. The protein content of the cell lysates was measured using the BioRad Protein Assay Kit. Cell lysates were resolved by sodium dodecyl sulfate polyacrylamide electrophoresis and transferred to an Immobilon-P membrane (Millipore, Bedford, MA). The membranes were incubated with antibodies for Sp1 (Millipore, Milford MA, 1:2000), HA (Abcam, 1:8000), DDDDK (MBL, Aichi, Japan 1:2000), Rev-erbα (Cell Signaling Technology [CST], Beverly, MA, 1:500), Cx43 (Sigma, St Louis, MO, 1:1000), Bmal1 (Santa Cruz Biotechnology, Santa Cruz, CA 1:200) and GAPDH (CST, 1:2000). The Rev-erbα antibody of CST (2124) was for 20 amino acids between 200 and 300 from the N terminus, including the H region. After incubation with HRP-conjugated anti-rabbit or anti-mouse secondary antibodies (Pierce, Rockford, IL), immunoreactive proteins were visualized using a Super Signal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL).

Co-immunoprecipitation assay: Preparation of nuclear extracts and co-immunoprecipitation were performed as previously described [17]. Briefly nuclear extracts were prepared from HEK293T cells in 10 cm dishes, transfected with HA-Rev-erbα or HA-Rev AB (3.75 μg), and DDDDK-Sp1 (3.75 μg) expression vectors for 48 h, using Nuclear Complex Co-IP kit (Active Motif, Carlsbad, CA). The 100 μg of nuclear extracts were incubated with 4 μg of antibodies for HA and control rabbit IgG (Zymed) in 500 μl of low IP buffer overnight at 4 °C with rotation followed by addition of 30 μl of Dynabeads Sheep anti-Rabbit IgG (Veritas, Tokyo, Japan) for 1 h. After washing with low IP buffer, the binding protein was eluted in 40 μl of RIPA buffer for immunoblotting. The 2 μg of nuclear extracts were used as input.

Statistical analysis: We used one-way ANOVA followed by Tukey's *post hoc* test for the multiple comparisons or by Dunnett's *post hoc* test for comparing to the control in the promoter–reporter assay, calculated with SPSS ver.11.0.1Jsoftware (SPSS Inc., Chicago, IL). A P value <0.05 was accepted as significant.

3. Results and discussion

3.1. Ligand is dispensable for activation by Rev-erbα with Sp1

Firstly, to investigate whether the transactivation of *Cx43* promoter by Rev-erbα/Sp1 complex is controlled by heme, the ligand of Rev-erbα as a nuclear receptor, we applied various concentrations of heme to the HEK293T cells transfected with Rev-erbα/Sp1. Exogenously applied heme showed little impact on the *Cx43* promoter activation (Fig. 1A), while it enhanced the suppressive effect on the abundance of Bmal1 protein as reported (Fig. 1B) [13,15]. In addition, SR8278, an antagonist of REV-ERB, was applied to block the action of endogenous agonist heme, which is always present in the cells [26]. It also had little effect on the *Cx43* promoter activation, which was not influenced by addition of GSK4112, an agonist of REV-ERB (Supplementary Fig. S1). Notably, although the ligand binding domain (LBD) of Rev-erbα has been reported to be crucial for recruiting co-repressors [14,15], a deletion mutant of LBD of Rev-erbα (Rev ΔLBD) still retained transactivation activity for the *Cx43* promoter (Fig. 1C). In contrast to the suppressive effect of Rev-erbα, the ligand is not considered to play a significant role in the transactivation mechanism.



Fig. 1. Ligand is dispensable for activation by the Rev-erbα and Sp1 complex. (A) Addition of hemin, a ligand of Rev-erbα, did not increase the effect of Rev-erbα and Sp1 on *Cx43* transcription. $N = 3$ for each group. (B) Bmal1 expression was decreased by addition of hemin on Rev-erbα and Sp1. (C) A mutant with deletion of the ligand binding domain (Δ287–610: RevΔLBD) still transactivated the *Cx43* promoter. $^*P < 0.0001$ compared with the control without transfection of Rev-erbα by one-way ANOVA followed by Dunnett's *post hoc* test. +, 125 ng in A and C. Error bars represent S.D. in A and C. For relative levels, Rev-erbα + Sp1 + hemin 0 μM was set to 1 in A, and the control as Rev-erbα – Sp1 – was set to 1 in C.